SAN DIEGO (PRWEB)
November 30, 2017
ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities. Central to this partnership will be the coupling of ACEA’s innovative xCELLigence® Real-Time Cell Analysis (RTCA) Cardio and CardioECR instruments with Ncardia’s fully functional Pluricyte® and Cor.4U® human iPSC-derived cardiomyocytes, providing a complete assay system for pure and applied cardiomyocyte research.
Ncardia, is an emerging drug discovery and development stem cell technology company whose goal is to be the trusted global leader in the hiPSC drug discovery and development field and the partner of choice for scientists operating in cardiovascular and neural safety and efficacy projects. Using its cell products, Ncardia develops and commercializes electrophysiology-, biochemistry-, and contraction-based assay services for predictive safety pharmacology, toxicology testing, and drug efficacy screening. In addition, the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Ncardia believes that stem cell technology fast-tracks the delivery of better medicines to patients by improving the drug discovery process.
ACEA is the developer of seven different xCELLigence® RTCA instruments, more than 2,000 of which have been installed in academic, industry, and government laboratories globally. The xCELLigence® RTCA CardioECR model is the only instrument in the world that combines high frequency (every 1 millisecond) measurement of cell-induced electrical impedance with multielectrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology in a microtiter plate format. Moreover, the CardioECR’s electrical pacing feature enables the functional maturation of cardiomyocytes, improving the efficacy and predictivity of…